Coherus Oncology (CHRS) Capital Expenditures (2013 - 2025)

Coherus Oncology (CHRS) has 13 years of Capital Expenditures data on file, last reported at $8.4 million in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures changed N/A year-over-year to $8.4 million; the trailing twelve-month figure through Dec 2025 stood at -$470.3 million (down 106.43% YoY), and the FY2025 full-year result was -$470.3 million, down 106.43% from the prior year.
• Capital Expenditures rose to $8.4 million in Q4 2025, from -$483.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $8.4 million in Q4 2025 to a low of -$483.4 million in Q2 2025.
• A 5-year average of -$43.4 million and a median of $206500.0 in 2021 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures soared 324.14% in 2022 and slumped 123667.76% in 2024, its largest moves.
• Tracing CHRS's Capital Expenditures over 5 years: stood at $468000.0 in 2021, then tumbled by 81.41% to $87000.0 in 2022, then plunged by 60.92% to $34000.0 in 2023, then slumped by 117747.06% to -$40.0 million in 2024, then jumped by 120.94% to $8.4 million in 2025.
• Business Quant data shows CHRS's Capital Expenditures at $8.4 million in Q4 2025, -$483.4 million in Q2 2025, and $4.7 million in Q1 2025.